TD Asset Management Inc Has $14.98 Million Stock Holdings in QuidelOrtho Corporation $QDEL

TD Asset Management Inc increased its holdings in QuidelOrtho Corporation (NASDAQ:QDEL) by 8.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 524,592 shares of the company’s stock after purchasing an additional 41,826 shares during the period. TD Asset Management Inc owned approximately 0.77% of QuidelOrtho worth $14,982,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Hantz Financial Services Inc. raised its position in QuidelOrtho by 50.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock worth $31,000 after purchasing an additional 362 shares in the last quarter. ProShare Advisors LLC raised its position in QuidelOrtho by 3.0% in the fourth quarter. ProShare Advisors LLC now owns 13,164 shares of the company’s stock worth $376,000 after purchasing an additional 388 shares in the last quarter. State of Alaska Department of Revenue raised its position in QuidelOrtho by 1.1% in the fourth quarter. State of Alaska Department of Revenue now owns 38,333 shares of the company’s stock worth $1,093,000 after purchasing an additional 424 shares in the last quarter. Moody National Bank Trust Division raised its position in QuidelOrtho by 1.0% in the fourth quarter. Moody National Bank Trust Division now owns 51,512 shares of the company’s stock worth $1,471,000 after purchasing an additional 526 shares in the last quarter. Finally, California State Teachers Retirement System raised its position in QuidelOrtho by 1.2% in the second quarter. California State Teachers Retirement System now owns 62,188 shares of the company’s stock worth $1,792,000 after purchasing an additional 725 shares in the last quarter. Institutional investors and hedge funds own 99.00% of the company’s stock.

QuidelOrtho Price Performance

Shares of QuidelOrtho stock opened at $14.47 on Tuesday. The company has a current ratio of 1.43, a quick ratio of 0.80 and a debt-to-equity ratio of 1.33. The stock has a market capitalization of $986.72 million, a price-to-earnings ratio of -0.81 and a beta of 0.77. QuidelOrtho Corporation has a 1-year low of $9.92 and a 1-year high of $35.58. The firm’s 50-day moving average price is $13.17 and its two-hundred day moving average price is $21.51.

QuidelOrtho (NASDAQ:QDEL) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.41). The firm had revenue of $619.80 million for the quarter, compared to the consensus estimate of $665.23 million. QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.QuidelOrtho’s quarterly revenue was down 10.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.74 earnings per share. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. On average, equities analysts predict that QuidelOrtho Corporation will post 1.83 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on QDEL shares. Jefferies Financial Group lowered shares of QuidelOrtho from a “buy” rating to a “hold” rating and dropped their price target for the stock from $35.00 to $12.50 in a research report on Thursday, May 7th. Wall Street Zen cut shares of QuidelOrtho from a “buy” rating to a “hold” rating in a research note on Sunday, April 12th. Citigroup decreased their price objective on shares of QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. UBS Group reaffirmed a “neutral” rating and set a $12.00 price objective on shares of QuidelOrtho in a research note on Thursday, May 7th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a research note on Tuesday, April 21st. Three investment analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, QuidelOrtho has a consensus rating of “Reduce” and an average target price of $14.88.

About QuidelOrtho

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.